# US 2003/0215850 A1 · Novel nucleic acid molecules and polypeptides encoding baboon TAFI

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215850 A1
- Document ID: US20030215850A1
- Status: Published application
- Kind: A1
- Application number: 10/379,836
- Filed: 2003-03-04
- Published: 2003-11-20
- Earliest claimed: 2002-03-04
- Assignees: Bristol-Myers Squibb Company
- Inventors: James K. Tamura; Gary R. Matsueda; Mei-Yin Hsu; Akbar Nayeem
- Web page: https://patentgrep.com/patent/US20030215850A1

## CPC

- C12N 9/48: acting on peptide bonds (3.4)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention. Such agonist or antagonist compounds may be useful in the treatment of various blood clotting disorders and conditions requiring hemostatic control such as hemophilia or various thrombotic diseases such as deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation and recurrent thrombosis following stroke or myocardial infarction.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: PTA 3949, which is hybridizable to SEQ ID NO:1;
(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: PTA 3949, which is hybridizable to SEQ ID NO:1;
(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No: PTA 3949, which is hybridizable to SEQ ID NO:1;
(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: PTA 3949, which is hybridizable to SEQ ID NO:1;
(e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: PTA 3949, which is hybridizable to SEQ ID NO:1, having thrombin-activatable fibrinolysis inhibitor activity;
(f) an isolated polynucleotide comprising nucleotides 4 to 1269 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 423 of SEQ ID NO:2 minus the start codon;
(g) an isolated polynucleotide comprising nucleotides 1 to 1269 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 423 of SEQ ID NO:2 including the start codon;
(h) an isolated polynucleotide comprising nucleotides 67 to 1269 of SEQ ID NO:1, wherein said nucleotides encode a mature polypeptide corresponding to amino acids 23 to 423 of SEQ ID NO:2;
(i) an isolated polynucleotide comprising nucleotides 67 to 345 of SEQ ID NO:1, wherein said nucleotides encode an activation polypeptide corresponding to amino acids 23 to 115 of SEQ ID NO:2;
(j) an isolated polynucleotide comprising nucleotides 346 to 1269 of SEQ ID NO:1, wherein said nucleotides encode polypeptide corresponding to amino acids 116 to 423 of SEQ ID NO:2;
(i) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1; and
(j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment consists of a nucleotide sequence encoding a baboon thrombin-activatable fibrinolysis inhibitor.

### Claim 3 (depends on 1)

A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

### Claim 4 (depends on 3)

A recombinant host cell comprising the vector sequences of claim 3.

### Claim 5

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA 3949;
(b) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA 3949, having thrombin-activatable fibrinolysis inhibitor activity;
(c) a polypeptide domain of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA 3949;
(d) a polypeptide epitope of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA 3949;
(e) a full length protein of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA 3949;
(f) an isolated polypeptide comprising amino acids 2 to 423 of SEQ ID NO:2;
(k) an isolated polypeptide comprising amino acids 1 to 423 of SEQ ID NO:2;
(l) an isolated mature polypeptide comprising amino acids 23 to 423 of SEQ ID NO:2;
(m) an isolated activation polypeptide comprising amino acids 23 to 115 of SEQ ID NO:2; and
(g) an isolated polypeptide comprising amino acids 116 to 423 of SEQ ID NO:2.

### Claim 6 (depends on 5)

The isolated polypeptide of claim 5, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

### Claim 7 (depends on 5)

An isolated antibody that binds specifically to the isolated polypeptide of claim 5.

### Claim 8 (depends on 5)

A recombinant host cell that expresses the isolated polypeptide of claim 5.

### Claim 9 (depends on 8)

A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 8 under conditions such that said polypeptide is expressed; and
(b) recovering said polypeptide.

### Claim 10 (depends on 9)

The polypeptide produced by claim 9.

### Claim 11 (depends on 5)

A method for preventing, treating, or ameliorating a medical condition, comprising the step of administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 5, or a modulator thereof.

### Claim 12 (depends on 1)

A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

### Claim 13 (depends on 5)

A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of claim 5 in a biological sample; and
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

### Claim 14

An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide of SEQ ID NO:2;
(b) an isolated polynucleotide consisting of nucleotides 4 to 1269 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 423 of SEQ ID NO:2 minus the start codon;
(c) an isolated polynucleotide consisting of nucleotides 1 to 1269 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 423 of SEQ ID NO:2 including the start codon;
(d) an isolated polynucleotide consisting of nucleotides 67 to 1269 of SEQ ID NO:1, wherein said nucleotides encode a mature polypeptide corresponding to amino acids 23 to 423 of SEQ ID NO:2;
(e) an isolated polynucleotide consisting of nucleotides 67 to 345 of SEQ ID NO:1, wherein said nucleotides encode an activation polypeptide corresponding to amino acids 23 to 115 of SEQ ID NO:2;
(f) an isolated polynucleotide consisting of nucleotides 346 to 1269 of SEQ ID NO:1, wherein said nucleotides encode polypeptide corresponding to amino acids 116 to 423 of SEQ ID NO:2; and
(c) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1.

### Claim 15 (depends on 14)

The isolated nucleic acid molecule of claim 14, wherein the polynucleotide comprises a nucleotide sequence encoding a baboon thrombin-activatable fibrinolysis inhibitor.

### Claim 16 (depends on 15)

A recombinant vector comprising the isolated nucleic acid molecule of claim 15.

### Claim 17 (depends on 16)

A recombinant host cell comprising the recombinant vector of claim 16.

### Claim 18

An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
(a) a polypeptide fragment of SEQ ID NO:2 having thrombin-activatable fibrinolysis inhibitor activity;
(b) a polypeptide domain of SEQ ID NO:2 having thrombin-activatable fibrinolysis inhibitor activity;
(c) a full length protein of SEQ ID NO:2;
(d) a polypeptide consisting of amino acids 2 to 423 of SEQ ID NO:2, wherein said amino acids 2 to 423 consisting of a polypeptide of SEQ ID NO:2 minus the start methionine;
(e) a polypeptide consisting of to amino acids 1 to 423 of SEQ ID NO:2;
(f) an isolated polypeptide consisting of amino acids 2 to 423 of SEQ ID NO:2;
(g) an isolated mature polypeptide consisting of amino acids 23 to 423 of SEQ ID NO:2;
(h) an isolated activation polypeptide consisting of amino acids 23 to 115 of SEQ ID NO:2; and
(i) an isolated polypeptide consisting of amino acids 116 to 423 of SEQ ID NO:2.

### Claim 19 (depends on 15)

The method of diagnosing a pathological condition of claim 15 wherein the condition is a member of the group consisting of: a disorder related to aberrant thrombin-activatable fibrinolysis inhibitor activity; a disorder associated with deficiencies in thrombin-activatable fibrinolysis inhibitor activity; a disorder associated with hyperthrombin-activatable fibrinolysis inhibitor activity; a disorder related to aberrant protease regulation; blood disorders wherein clotting needs to be regulated or promoted, hemophilia, von Willebrand's disease, aberrant bleeding regulation subsequent to trauma, thrombotic diseases, deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation, recurrent thrombosis following stroke, recurrent thrombosis following myocardial infarction; fibrinolytic disorders; and Factor VIII deficiencies; hemophilia A.

### Claim 20 (depends on 11)

The method for preventing, treating, or ameliorating a medical condition of claim 11, wherein the medical condition is selected from the group consisting of: a disorder related to aberrant thrombin-activatable fibrinolysis inhibitor activity; a disorder associated with deficiencies in thrombin-activatable fibrinolysis inhibitor activity; a disorder associated with hyperthrombin-activatable fibrinolysis inhibitor activity; a disorder related to aberrant protease regulation; blood disorders wherein clotting needs to be regulated or promoted, hemophilia, von Willebrand's disease, aberrant bleeding regulation subsequent to trauma, thrombotic diseases, deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation, recurrent thrombosis following stroke, recurrent thrombosis following myocardial infarction; fibrinolytic disorders; and Factor VIII deficiencies; hemophilia A.

### Claim 21

A computer for producing a three-dimensional representation of a molecule or molecular complex, wherein said molecule or molecular complex comprises the structural coordinates of baboon TAFI provided in accordance with Table I, wherein said computer comprises:
(a) A machine-readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the data is defined by the set of structure coordinates of the model;
(b) a working memory for storing instructions for processing said machine-readable data;
(c) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine readable data into said three-dimensional representation; and
(d) a display coupled to said central-processing unit for displaying said three-dimensional representation.

### Claim 22

A method for identifying a mutant with altered biological properties, function, or activity of baboon TAFI, wherein said method comprises the steps of:
(a) using a model of said polypeptide according to the structural coordinates of said model to identify amino acids to mutate; and
(b) mutating said amino acids to create a mutant protein with altered biological function or properties.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the mutant is a member of the group consisting of:
(a) a mutant with mutations in the catalytic domain of baboon TAFI comprised of amino acids from about D63 to about D274 of SEQ ID NO:2 according to Table I with altered thrombin-activatable fibrinolysis inhibitor function or properties; and
(b) a mutant with mutations in one or more catalytic amino acid residues within the baboon TAFI active site comprised of amino acids H181, E184, and H310 of SEQ ID NO:2 according to Table I with altered thrombin-activatable fibrinolysis inhibitor function or properties.

### Claim 24

A method for designing or selecting compounds as potential modulators of baboon TAFI, wherein said method comprises the steps of:
(a) identifying a structural or chemical feature of said member using the structural coordinates of said member; and
(b) rationally designing compounds that bind to said feature.

### Claim 25

A computer for producing a three-dimensional representation of a molecule or molecular complex, wherein said molecule or molecular complex comprises the structural coordinates of human TAFI provided in accordance with Table II, wherein said computer comprises:
(a) A machine-readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the data is defined by the set of structure coordinates of the model;
(b) a working memory for storing instructions for processing said machine-readable data;
(c) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine readable data into said three-dimensional representation; and
(d) a display coupled to said central-processing unit for displaying said three-dimensional representation.

### Claim 26

A method for identifying a mutant with altered biological properties, function, or activity of human TAFI, wherein said method comprises the steps of:
(a) using a model of said polypeptide according to the structural coordinates of said model to identify amino acids to mutate; and
(b) mutating said amino acids to create a mutant protein with altered biological function or properties.

### Claim 27 (depends on 26)

The method according to claim 26 wherein the mutant is a member of the group consisting of:
(a) a mutant with mutations in the catalytic domain of human TAFI comprised of amino acids from about D63 to about D274 of SEQ ID NO:17 according to Table II with altered thrombin-activatable fibrinolysis inhibitor function or properties; and
(b) a mutant with mutations in one or more catalytic amino acid residues within the human TAFI active site comprised of amino acids H181, E184, and H310 of SEQ ID NO:17 according to Table II with altered thrombin-activatable fibrinolysis inhibitor function or properties.

### Claim 28

A method for designing or selecting compounds as potential modulators of human TAFI, wherein said method comprises the steps of:
(a) identifying a structural or chemical feature of said member using the structural coordinates of said member; and

### Claim 29

rationally designing compounds that bind to said feature.

### Claim 30 (depends on 1)

An isolated polynucleotide comprising a polynucleotide having a nucleotide sequence at least 96.3% identical to a sequence provided in claim 1, wherein percent identity is calculated using a CLUSTALW global sequence alignment.

### Claim 31 (depends on 5)

An isolated polypeptide comprising a polypeptide having an amino acid sequence at least 94.4% identical to a sequence provided in claim 5, wherein percent identity is calculated using a CLUSTALW global sequence alignment.
